(ATRC) AtriCure - Overview

Sector: Healthcare | Industry: Medical Instruments & Supplies | Exchange: NASDAQ (USA) | Market Cap: 1.410m USD | Total Return: -8% in 12m

Surgical Devices, Ablation Systems, Nerve Block
Total Rating 32
Safety 30
Buy Signal 0.18
Medical Instruments & Supplies
Industry Rotation: -3.8
Market Cap: 1.41B
Avg Turnover: 15.1M USD
ATR: 4.51%
Peers RS (IBD): 27.0
Risk 5d forecast
Volatility48.8%
Rel. Tail Risk-7.27%
Reward TTM
Sharpe Ratio-0.20
Alpha-26.68
Character TTM
Beta0.683
Beta Downside1.724
Drawdowns 3y
Max DD65.60%
CAGR/Max DD-0.16
EPS (Earnings per Share) EPS (Earnings per Share) of ATRC over the last years for every Quarter: "2021-03": -0.38, "2021-06": -0.36, "2021-09": 2.11, "2021-12": -0.3, "2022-03": -0.33, "2022-06": -0.32, "2022-09": -0.27, "2022-12": -0.09, "2023-03": -0.23, "2023-06": -0.11, "2023-09": -0.2, "2023-12": -0.21, "2024-03": -0.28, "2024-06": -0.17, "2024-09": -0.17, "2024-12": -0.08, "2025-03": -0.14, "2025-06": -0.02, "2025-09": -0.01, "2025-12": 0.06, "2026-03": 0,
EPS CAGR: 127.04%
EPS Trend: 78.7%
Last SUE: 1.56
Qual. Beats: 6
Revenue Revenue of ATRC over the last years for every Quarter: 2021-03: 59.275, 2021-06: 71.376, 2021-09: 70.46, 2021-12: 73.218, 2022-03: 74.576, 2022-06: 84.529, 2022-09: 83.246, 2022-12: 88.028, 2023-03: 93.494, 2023-06: 100.918, 2023-09: 98.29, 2023-12: 106.543, 2024-03: 108.851, 2024-06: 116.269, 2024-09: 115.91, 2024-12: 124.277, 2025-03: 123.62, 2025-06: 136.139, 2025-09: 134.269, 2025-12: 140.5, 2026-03: null,
Rev. CAGR: 18.40%
Rev. Trend: 98.8%
Last SUE: 0.38
Qual. Beats: 0
Warnings

Interest Coverage Ratio -0.4 is critical

Altman Z'' -2.34 < 1.0 - financial distress zone

Tailwinds

No distinct edge detected

Description: ATRC AtriCure

AtriCure, Inc. (ATRC) develops and sells medical devices for cardiac tissue ablation, left atrial appendage exclusion, and pain management.

The companys product portfolio includes systems for treating cardiac arrhythmias, such as the Isolator Synergy Ablation System and the EPi-Sense Systems. These devices are used in surgical procedures to correct irregular heartbeats. The medical device sector is characterized by stringent regulatory oversight and a focus on innovative technologies to improve patient outcomes.

ATRC also offers cryoablation systems like the cryoICE Cryoablation System and cryoSPHERE probes for temporary pain relief. Its AtriClip System is an implantable device for left atrial appendage exclusion, a procedure aimed at reducing stroke risk in patients with atrial fibrillation. The business model relies on both direct sales and independent distributors to reach medical centers globally.

For a detailed financial analysis of AtriCure, Inc., consider exploring its profile on ValueRay.

Headlines to Watch Out For
  • Atrial fibrillation device sales drive revenue growth
  • Cryoablation technology expands pain management market
  • Regulatory approvals impact new product launches
  • International market expansion boosts sales volume
Piotroski VR‑10 (Strict) 5.5
Net Income: -11.4m TTM > 0 and > 6% of Revenue
FCF/TA: 0.07 > 0.02 and ΔFCF/TA 9.37 > 1.0
NWC/Revenue: 45.09% < 20% (prev 41.78%; Δ 3.31% < -1%)
CFO/TA 0.09 > 3% & CFO 57.3m > Net Income -11.4m
Net Debt (-79.4m) to EBITDA (11.7m): -6.77 < 3
Current Ratio: 3.96 > 1.5 & < 3
Outstanding Shares: last quarter (48.9m) vs 12m ago 3.75% < -2%
Gross Margin: 74.84% > 18% (prev 0.74%; Δ 7.41k% > 0.5%)
Asset Turnover: 84.61% > 50% (prev 76.36%; Δ 8.25% > 0%)
Interest Coverage Ratio: -0.39 > 6 (EBITDA TTM 11.7m / Interest Expense TTM 7.32m)
Altman Z'' -2.34
A: 0.37 (Total Current Assets 322.5m - Total Current Liabilities 81.5m) / Total Assets 654.2m
B: -0.63 (Retained Earnings -413.2m / Total Assets 654.2m)
C: -0.00 (EBIT TTM -2.85m / Avg Total Assets 631.8m)
D: -2.54 (Book Value of Equity -412.6m / Total Liabilities 162.2m)
Altman-Z'' Score: -2.34 = D
Beneish M -3.12
DSRI: 0.96 (Receivables 66.7m/60.3m, Revenue 534.5m/465.3m)
GMI: 0.99 (GM 74.84% / 74.37%)
AQI: 0.90 (AQ_t 0.44 / AQ_t-1 0.48)
SGI: 1.15 (Revenue 534.5m / 465.3m)
TATA: -0.11 (NI -11.4m - CFO 57.3m) / TA 654.2m)
Beneish M-Score: -3.12 (Cap -4..+1) = AA
What is the price of ATRC shares? As of April 06, 2026, the stock is trading at USD 29.07 with a total of 512,100 shares traded.
Over the past week, the price has changed by +2.87%, over one month by -4.09%, over three months by -28.26% and over the past year by -7.98%.
Is ATRC a buy, sell or hold? AtriCure has received a consensus analysts rating of 4.56. Therefore, it is recommended to buy ATRC.
  • StrongBuy: 5
  • Buy: 4
  • Hold: 0
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the ATRC price?
Analysts Target Price 47.9 64.7%
AtriCure (ATRC) - Fundamental Data Overview as of 02 April 2026
P/E Forward = 384.6154
P/S = 2.6381
P/B = 2.8908
P/EG = 10.0
Revenue TTM = 534.5m USD
EBIT TTM = -2.85m USD
EBITDA TTM = 11.7m USD
Long Term Debt = 61.9m USD (from longTermDebt, last quarter)
Short Term Debt = 3.12m USD (from shortTermDebt, last quarter)
Debt = 88.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -79.4m USD (from netDebt column, last quarter)
Enterprise Value = 1.33b USD (1.41b + Debt 88.0m - CCE 167.4m)
Interest Coverage Ratio = -0.39 (Ebit TTM -2.85m / Interest Expense TTM 7.32m)
EV/FCF = 27.56x (Enterprise Value 1.33b / FCF TTM 48.3m)
FCF Yield = 3.63% (FCF TTM 48.3m / Enterprise Value 1.33b)
FCF Margin = 9.03% (FCF TTM 48.3m / Revenue TTM 534.5m)
Net Margin = -2.14% (Net Income TTM -11.4m / Revenue TTM 534.5m)
Gross Margin = 74.84% ((Revenue TTM 534.5m - Cost of Revenue TTM 134.5m) / Revenue TTM)
Gross Margin QoQ = 74.43% (prev 75.47%)
Tobins Q-Ratio = 2.03 (Enterprise Value 1.33b / Total Assets 654.2m)
Interest Expense / Debt = 1.71% (Interest Expense 1.50m / Debt 88.0m)
Taxrate = 25.59% (604k / 2.36m)
NOPAT = -2.12m (EBIT -2.85m * (1 - 25.59%)) [loss with tax shield]
Current Ratio = 3.96 (Total Current Assets 322.5m / Total Current Liabilities 81.5m)
Debt / Equity = 0.18 (Debt 88.0m / totalStockholderEquity, last quarter 491.9m)
Debt / EBITDA = -6.77 (Net Debt -79.4m / EBITDA 11.7m)
Debt / FCF = -1.64 (Net Debt -79.4m / FCF TTM 48.3m)
Total Stockholder Equity = 471.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -1.81% (Net Income -11.4m / Total Assets 654.2m)
RoE = -2.43% (Net Income TTM -11.4m / Total Stockholder Equity 471.9m)
RoCE = -0.53% (EBIT -2.85m / Capital Employed (Equity 471.9m + L.T.Debt 61.9m))
 RoIC = -0.40% (negative operating profit) (NOPAT -2.12m / Invested Capital 533.8m)
 WACC = 7.97% (E(1.41b)/V(1.50b) * Re(8.39%) + D(88.0m)/V(1.50b) * Rd(1.71%) * (1-Tc(0.26)))
Discount Rate = 8.39% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 2.58%
[DCF] Terminal Value 70.82% ; FCFF base≈48.3m ; Y1≈31.7m ; Y5≈14.5m
[DCF] Fair Price = 7.40 (EV 289.0m - Net Debt -79.4m = Equity 368.4m / Shares 49.8m; r=7.97% [WACC]; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 78.65 | EPS CAGR: 127.0% | SUE: 1.56 | # QB: 6
Revenue Correlation: 98.75 | Revenue CAGR: 18.40% | SUE: 0.38 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.03 | Chg7d=-0.001 | Chg30d=-0.001 | Revisions Net=+7 | Analysts=8
EPS current Year (2026-12-31): EPS=0.13 | Chg7d=+0.000 | Chg30d=+0.000 | Revisions Net=+7 | Growth EPS=+214.2% | Growth Revenue=+13.0%
EPS next Year (2027-12-31): EPS=0.37 | Chg7d=+0.034 | Chg30d=+0.034 | Revisions Net=+4 | Growth EPS=+194.1% | Growth Revenue=+12.2%
[Analyst] Revisions Ratio: +1.00 (7 Up / 0 Down within 30d for Next Quarter)
External Resources
Dataroma Stockcircle